GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

Two days after Monte Rosa Therapeutics Inc. signed a molecular glue degrader deal with Novartis AG, two other companies, ...

Neomorph will receive an upfront payment and may earn contingent milestone payments as the collaboration advances.

US biotech companies Biogen and Neomorph have announced a research collaboration to discover and develop molecular glue ...

Biogen touted strong Q3 sales of its Alzheimer’s drug Leqembi a day after announcing a deal worth up to $1.45 billion with ...

Biogen is the latest big biotech to make a play in protein degradation. The Massachusetts-based company has announced a deal to use Neomorph’s molecular glue degrader discovery platform to go after ...

Biogen Inc. (BIIB) and Neomorph Inc. announced a research collaboration to discover and develop molecular glue degraders for priority ...

Biogen (BIIB) announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer’s, ...

VANCOUVER, British Columbia, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Tactical Resources Corp. (TSXV: RARE) (OTC: USREF) ("Tactical ...

Biogen partners with Neomorph to develop molecular glue degraders for Alzheimer's and other diseases, offering up to $1.45B in payments.

AbbVie has entered a definitive agreement to acquire all outstanding equity of Aliada Therapeutics in a deal valued at $1.4bn ...

The US FDA has approved Iterum Therapeutics' NDA for ORLYNVAH to treat uncomplicated urinary tract infections (uUTIs).